Feedback / Questions
BOW100 (golimumab biosimilar) - Epirus
Epirus: Corporate Overview
(Epirus Biopharmaceuticals)
-
Feb 7, 2016 -
Anticipated global filings for inflammatory diseases in 2022
Anticipated regulatory
•
Biosimilar
http://files.shareholder.com/downloads/AMDA-30YNO0/1471780370x0x872165/D50CA62A-2940-4B94-A5BF-06ECC0C3C773/Corp_Slide_deck.pdf
Feb 7, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
.